Furthermore, treatment with the pan-hydroxylase inhibitor DMOG suppressed cell proliferation and increased cell death across multiple prostate cancer cell lines (Figure 6C–F), recapitulating the phenotypes observed with PHD1 and PHD3 knockdown. This evidence concerns the gene EGLN2 and prostate carcinoma.